261 related articles for article (PubMed ID: 17673059)
1. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
[TBL] [Abstract][Full Text] [Related]
2. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
3. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients.
Chao TY; Yu JC; Ku CH; Chen MM; Lee SH; Janckila AJ; Yam LT
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):544-50. PubMed ID: 15701839
[TBL] [Abstract][Full Text] [Related]
4. Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients.
Yao NS; Wu YY; Janckila AJ; Ku CH; Hsieh AT; Ho CL; Lee SH; Chao TY
Clin Chim Acta; 2011 Jan; 412(1-2):181-5. PubMed ID: 20932965
[TBL] [Abstract][Full Text] [Related]
5. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
[TBL] [Abstract][Full Text] [Related]
6. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
[TBL] [Abstract][Full Text] [Related]
7. Serum Levels of NTx and TRACP5b in Giant Cell Tumor of Bone and its Clinical Implications.
Chen J; Younusi A; Cao L; Xu L; Zhou Y; Zhen T; Song X
Clin Lab; 2015; 61(8):1077-81. PubMed ID: 26427154
[TBL] [Abstract][Full Text] [Related]
8. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer.
Wada N; Ishii S; Ikeda T; Enomoto K; Kitajima M
Anticancer Res; 1999; 19(5C):4515-21. PubMed ID: 10650803
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer.
Capeller B; Caffier H; Sütterlin MW; Dietl J
Anticancer Res; 2003; 23(2A):1011-5. PubMed ID: 12820340
[TBL] [Abstract][Full Text] [Related]
10. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y
Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
[TBL] [Abstract][Full Text] [Related]
11. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.
Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM
J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501
[TBL] [Abstract][Full Text] [Related]
12. Age-related changes of serum tartrate-resistant acid phosphatase 5b and the relationship with bone mineral density in Chinese women.
Qin YJ; Zhang ZL; Zhang H; Hu WW; Liu YJ; Hu YQ; Li M; Gu JM; He JW
Acta Pharmacol Sin; 2008 Dec; 29(12):1493-8. PubMed ID: 19026169
[TBL] [Abstract][Full Text] [Related]
13. Detection of Bone Metastases in Breast Cancer (BC) Patients by Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b), a Bone Resorption Marker and Serum Alkaline Phosphatase (ALP), a Bone Formation Marker, in Lieu of Whole Body Skeletal Scintigraphy with Technetium99m MDP.
Sarvari BK; Sankara Mahadev D; Rupa S; Mastan SA
Indian J Clin Biochem; 2015 Jan; 30(1):66-71. PubMed ID: 25646043
[TBL] [Abstract][Full Text] [Related]
14. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
15. Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis.
Chao TY; Wu YY; Janckila AJ
Clin Chim Acta; 2010 Nov; 411(21-22):1553-64. PubMed ID: 20599857
[TBL] [Abstract][Full Text] [Related]
16. Postoperative expressions of TRACP5b and CA125 in patients with breast cancer and their values for monitoring bone metastasis.
Feng C; Zhan Y; Shao H; Wang Z; Zhu S
J BUON; 2020; 25(2):688-695. PubMed ID: 32521854
[TBL] [Abstract][Full Text] [Related]
17. Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients.
Mose S; Menzel C; Kurth AA; Obert K; Breidert I; Borowsky K; Böttcher HD
Anticancer Res; 2003; 23(3C):2783-8. PubMed ID: 12926113
[TBL] [Abstract][Full Text] [Related]
18. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption.
Halleen JM
Anticancer Res; 2003; 23(2A):1027-9. PubMed ID: 12820342
[TBL] [Abstract][Full Text] [Related]
19. Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients.
Chao TY; Ho CL; Lee SH; Chen MM; Janckila A; Yam LT
J Biomed Sci; 2004; 11(4):511-6. PubMed ID: 15153786
[TBL] [Abstract][Full Text] [Related]
20. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
